SCHEMBL524159

SCHEMBL524159

C[C@@H](Oc1nc(-c2ccc(=O)[nH]c2)cc2ncccc12)C1CNC(=O)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 1.00
FLT3 P36888 1/20 0.69
AURKB Q96GD4 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524158 1.00 SYK (1.00) SYKFLT3AURKB
SCHEMBL10196754 0.88 SYK (1.00) SYK
SCHEMBL10196746 0.88 SYK (1.00) SYK
SCHEMBL10258161 0.87 SYK (0.84) SYK
SCHEMBL12435330 0.86 SYK (1.00) SYKFLT3AURKB
SCHEMBL10196488 0.86 SYK (1.00) SYKFLT3AURKB
SCHEMBL10196476 0.86 SYK (1.00) SYKFLT3AURKB
SCHEMBL10196471 0.86 SYK (1.00) SYKFLT3AURKB
SCHEMBL10196627 0.85 SYK (1.00) SYKFLT3AURKB
SCHEMBL10196698 0.85 SYK (1.00) SYKFLT3AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187478-B2 Substituted naphthyridines and their use as medicaments Boehringer Ingellheim International GmbH (DE) 2015-11-17 US disclosed
US-20150126503-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2015-05-07 US disclosed
US-8969568-B2 Substituted naphthyridines and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2015-03-03 US disclosed
US-20120028939-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028939-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS NR4A3, NR0B1, NR4A1 SYK 3856/4885FLT3 2613/4885AURKB 3853/4885
US-20150126503-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS NR4A3, NR0B1, NR4A1 SYK 3856/4885FLT3 2613/4885AURKB 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.